US20080279966A1 - Branched-chain amino acid composition for improving skeletal muscle protein metabolism - Google Patents
Branched-chain amino acid composition for improving skeletal muscle protein metabolism Download PDFInfo
- Publication number
- US20080279966A1 US20080279966A1 US11/745,859 US74585907A US2008279966A1 US 20080279966 A1 US20080279966 A1 US 20080279966A1 US 74585907 A US74585907 A US 74585907A US 2008279966 A1 US2008279966 A1 US 2008279966A1
- Authority
- US
- United States
- Prior art keywords
- composition
- skeletal muscle
- acts
- derivatives
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002027 skeletal muscle Anatomy 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 102000008934 Muscle Proteins Human genes 0.000 title claims abstract description 24
- 108010074084 Muscle Proteins Proteins 0.000 title claims abstract description 24
- 150000005693 branched-chain amino acids Chemical class 0.000 title claims description 22
- 230000022558 protein metabolic process Effects 0.000 title abstract description 7
- 238000001243 protein synthesis Methods 0.000 claims abstract description 12
- 230000014616 translation Effects 0.000 claims abstract description 12
- 230000017854 proteolysis Effects 0.000 claims abstract description 4
- JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 claims description 17
- 108010057466 NF-kappa B Proteins 0.000 claims description 16
- 102000003945 NF-kappa B Human genes 0.000 claims description 16
- 244000118350 Andrographis paniculata Species 0.000 claims description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 235000012754 curcumin Nutrition 0.000 claims description 10
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 8
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 229940117360 ethyl pyruvate Drugs 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 230000024883 vasodilation Effects 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 abstract description 9
- 230000011664 signaling Effects 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 description 21
- 230000015556 catabolic process Effects 0.000 description 7
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 5
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000007894 caplet Substances 0.000 description 4
- 229960004203 carnitine Drugs 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- JDTWZSUNGHMMJM-UHFFFAOYSA-N N-acetyl-DL-alloisoleucine Natural products CCC(C)C(C(O)=O)NC(C)=O JDTWZSUNGHMMJM-UHFFFAOYSA-N 0.000 description 2
- JDTWZSUNGHMMJM-FSPLSTOPSA-N N-acetyl-L-isoleucine Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(C)=O JDTWZSUNGHMMJM-FSPLSTOPSA-N 0.000 description 2
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 2
- IHYJTAOFMMMOPX-LURJTMIESA-N N-acetyl-L-valine Chemical compound CC(C)[C@@H](C(O)=O)NC(C)=O IHYJTAOFMMMOPX-LURJTMIESA-N 0.000 description 2
- NOUDPBCEONUCOV-FJXQXJEOSA-N [(2s)-1-ethoxy-4-methyl-1-oxopentan-2-yl]azanium;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC(C)C NOUDPBCEONUCOV-FJXQXJEOSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 description 2
- ICPWNTVICOHCML-BQBZGAKWSA-N ethyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CCOC(=O)[C@@H](N)[C@@H](C)CC ICPWNTVICOHCML-BQBZGAKWSA-N 0.000 description 2
- KJSZRMCHQUWQSJ-UHFFFAOYSA-N ethyl 2-oxopropanoate;2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O.CCOC(=O)C(C)=O KJSZRMCHQUWQSJ-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 108010067121 Gamma-butyrobetaine dioxygenase Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 102000052653 gamma-Butyrobetaine Dioxygenase Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 1
- 229960002937 meldonium Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000013663 muscle adaptation Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
Definitions
- the present invention relates to a nutritional composition for improving the protein metabolism of skeletal muscles. A method of the same is also provided.
- Body composition including muscle, is influenced both by genetic factors and environmental stimuli. Genetic factors are typically difficult, if not impossible to alter through intervention. Environmental factors however are routinely manipulated and important environmental factors that effect muscle metabolism, such as food intake and exercise, effect muscle metabolism within hours of stimulation A Gene and protein expression patterns change in response to these stimuli. These changes result in muscle adaptations such as muscle atrophy (loss) via muscle protein catabolism (breakdown) or muscle hypertrophy (increase) via muscle protein accretion. These opposing actions are not mutually exclusive and the determination of muscle loss or gain is the net effect of both positive and negative factors governing muscle development.
- Exercise is a major stimulus of skeletal muscle growth. During several hours post-exercise there are dynamic changes in the rates of both skeletal muscle synthesis and breakdown. The consumption of specific dietary components is known to further influence the response of skeletal muscle to exercise.
- the main component of food that is known to stimulate increased muscle protein synthesis is amino acids (Rennie M J. Body maintenance and repair: how food and exercise keep the musculoskeletal system in good shape. Exp Physiol. July 2005;90(4):427-36).
- Increased levels of circulating essential amino acids have been shown to stimulate protein synthesis (Smith K, Reynolds N, Downie S, Patel A, Rennie M J. Effects of flooding amino acids on incorporation of labeled amino acids into human muscle protein. Am J Physiol. July 1998;275(1 Pt 1):E73-8).
- NF- ⁇ B Nuclear Factor kappa B
- the present invention comprises one or more branched-chain amino acids or derivatives thereof, a plant extract for attenuating NF- ⁇ B signaling, and ⁇ -butyrobetaine or derivative thereof for inducing vasodilation.
- Administration of the composition of present invention provides a method for improving the skeletal muscle protein metabolism of an individual.
- the present invention is directed towards improving skeletal muscle protein metabolism, both in terms of promoting increased muscle protein accrual via increased protein synthesis and in terms of reducing the breakdown of skeletal muscle protein.
- the present invention is particularly useful for individuals engaged in regular intense physical activity who wish to gain lean muscle mass and size or minimize muscle loss.
- a nutritional composition comprised of BCAAs.
- BCAAs employed may be selected from Leucine, Isoleucine and Valine or derivatives of each thereof.
- a nutritional composition comprised of BCAAs and at least one ingredient known to attenuate NF- ⁇ B signaling is provided.
- the ingredient known to attenuate NF- ⁇ B signaling is an extract of Andrographis paniculata.
- a nutritional composition comprised of BCAAs, at least one ingredient known to attenuate NF- ⁇ B signaling and at least one ingredient known to increase vasodilation via increased levels of nitric oxide is provided.
- the ingredient known to increase vasodilation via increased levels of nitric oxide is ⁇ -butyrobetaine or derivatives thereof.
- a nutritional composition comprised of Leucine, Isoleucine and Valine or derivatives of each thereof, an extract of Andrographis paniculata and ⁇ -butyrobetaine or derivatives thereof is provided for improving skeletal muscle protein metabolism.
- BCAAs branched-chain amino acids
- the branched-chain amino acids consist of Leucine, Isoleucine and Valine. BCAAs are considered essential since humans cannot synthesis them—they must be obtained from the diet—despite their importance. They are not only used in the synthesis of other amino acids but are important in the regulation of the anabolic process in skeletal muscle. BCAAs not only increase the rate of protein synthesis but also inhibit protein degradation (Matthews D E. Observations of branched-chain amino acid administration in humans. J Nutr. June 2005;135(6 Suppl):1580S-4S).
- the nutritional supplement comprises BCAAs or derivatives thereof.
- the amount of BCAAs or derivatives thereof in a serving of the nutritional supplement is from about 0.7 g to about 10.5 g.
- the preferred embodiment of the present invention comprises the BCAAs Leucine, Isoleucine and Valine or derivatives of each thereof in the following amounts.
- a serving of the nutritional supplement comprises Leucine or derivatives thereof from about 0.5 g to about 8.0 g.
- a serving of the nutritional supplement comprises Isoleucine or derivatives thereof from about 0.07 g to about 3.0 g.
- a serving of the nutritional supplement comprises Valine or derivatives thereof from about 0.1 g to about 3.5 g.
- the ratio of Isoleucine to Leucine to Valine in the nutritional composition is about 1 to 2.3 to 1.2.
- Andrographis paniculata is a medicinal herb used traditionally throughout Asia used to treat a number of conditions.
- One of the active ingredients of Andrographis paniculata extract is the diterpene, andrographolide.
- Andrographolide is known to inhibit the activity of NF- ⁇ B by interfering with the binding of NF- ⁇ B to DNA (Hidalgo M A, Romero A, Figueroa J, Cortes P, Concha I I, Hancke J L, Burgos R A. Andrographolide interferes with binding to nuclear factor- ⁇ B to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol. March 2005;144(5):680-6).
- the nutritional supplement comprises an extract of Andrographis paniculata.
- the amount of Andrographis paniculata extract in a serving of the nutritional supplement is from about 0.05 g to about 1 g.
- the preferred amount of Andrographis paniculata extract in a serving of the nutritional supplement is about 0.1 g.
- the present invention may also include additional components known to attenuate NF- ⁇ B-mediated signaling to promote the efficacy of the composition.
- the nutritional supplement may further comprise Diferuloylmethane (Curcumin) (Singh S, Aggarwal B B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] J Biol Chem. Oct. 20, 1995;270(42):24995-5000. Erratum in: J Biol Chem Dec. 15, 1995;270(50):30235) or Ethyl pyruvate (Pyruvic Acid Ethyl Ester) (Das UN. Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. Med Sci Monit. May 2006;12(5):RA79-84). Ethyl pyruvate also has the benefit of providing an energy substrate beta-oxidation in the mit
- ⁇ -butyrobetaine is an intermediate in carnitine biosynthesis in mammals. It is synthesized, from trimethyl lysine, in almost all cell types and then excreted into the blood to be reabsorbed by the kidney and liver. After reabsorption, ⁇ -butyrobetaine is converted to carnitine by ⁇ -butyrobetaine dioxygenase. This conversion to carnitine is extremely efficient, thus presence of ⁇ -butyrobetaine in urine is very small (Vaz F M, Wanders R J A. Carnitine biosynthesis in mammals. Biochem J. 2002;361:417-429).
- the nutritional supplement comprises ⁇ -butyrobetaine or derivatives thereof.
- the amount of ⁇ -butyrobetaine or derivatives thereof in a serving of the nutritional supplement is from about 0.01 g to about 1 g.
- the preferred amount of ⁇ -butyrobetaine or derivatives thereof in a serving of the nutritional supplement is about 0.2 g.
- the components of the present invention will act synergistically and simultaneously to promote improved protein metabolism in skeletal muscles.
- the BCAAs or derivatives thereof will act to increase skeletal muscle protein synthesis while decreasing skeletal muscle protein breakdown;
- the Andrographis paniculata extract and other like-directed components will act to attenuate inflammatory signals mediated by NF- ⁇ B resulting from intense exercise;
- the of ⁇ -butyrobetaine or derivatives thereof will act to vasodilate blood vessels via increase nitric oxide to facilitate the delivery of nutrients to active or recovering skeletal muscles.
- the nutritional supplement may be consumed in any form.
- the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel.
- the preferred dosage form of the present invention is a caplet.
- the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above.
- the nutritional supplement set forth in the example embodiment herein may contain any appropriate number and type of excipients, as is well known in the art.
- specific excipients as well as specific dosage formats may be utilized to achieve specific controlled-release of active ingredients.
- Such formats include but are not limited to quick-release, timed-release, slow-release and delayed-release.
- the present nutritional composition or those similarly envisioned by one of skill in the art, may be utilized in methods to improve skeletal muscle protein synthesis. As such, the present invention may be utilized as a sole means of improving skeletal muscle protein synthesis or in combination with other like-directed compounds.
- One serving of the nutritional supplement contains the following:
- One serving of the nutritional supplement contains the following:
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to compositions and methods for improving skeletal muscle protein metabolism through encouraging skeletal muscle protein synthesis, reducing skeletal muscle protein degradation, and attenuating inflammatory signaling in exercising muscle.
Description
- The present invention relates to a nutritional composition for improving the protein metabolism of skeletal muscles. A method of the same is also provided.
- Body composition, including muscle, is influenced both by genetic factors and environmental stimuli. Genetic factors are typically difficult, if not impossible to alter through intervention. Environmental factors however are routinely manipulated and important environmental factors that effect muscle metabolism, such as food intake and exercise, effect muscle metabolism within hours of stimulation A Gene and protein expression patterns change in response to these stimuli. These changes result in muscle adaptations such as muscle atrophy (loss) via muscle protein catabolism (breakdown) or muscle hypertrophy (increase) via muscle protein accretion. These opposing actions are not mutually exclusive and the determination of muscle loss or gain is the net effect of both positive and negative factors governing muscle development.
- Exercise is a major stimulus of skeletal muscle growth. During several hours post-exercise there are dynamic changes in the rates of both skeletal muscle synthesis and breakdown. The consumption of specific dietary components is known to further influence the response of skeletal muscle to exercise. The main component of food that is known to stimulate increased muscle protein synthesis is amino acids (Rennie M J. Body maintenance and repair: how food and exercise keep the musculoskeletal system in good shape. Exp Physiol. July 2005;90(4):427-36). Increased levels of circulating essential amino acids have been shown to stimulate protein synthesis (Smith K, Reynolds N, Downie S, Patel A, Rennie M J. Effects of flooding amino acids on incorporation of labeled amino acids into human muscle protein. Am J Physiol. July 1998;275(1 Pt 1):E73-8).
- Exercise stimulates inflammatory pathways which contribute to anabolic responses. However, excessive activation of inflammatory signaling molecules such as Nuclear Factor kappa B (NF-κB) has been implicated in several disease states involving loss or weakening of muscle (Kramer H F, Goodyear L J. Exercise, MAPK, and NF-{kappa}B Signaling in Skeletal Muscle. J Appl Physiol. Feb. 15, 2007). In these situations skeletal muscle protein breakdown exceeds protein synthesis.
- It would therefore be advantageous for an individual concerned with maintaining or increasing lean skeletal muscle mass to consume a nutritional composition directed at improving skeletal muscle metabolism, to encourage skeletal muscle protein synthesis while minimizing skeletal muscle protein breakdown.
- The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention, which comprises one or more branched-chain amino acids or derivatives thereof, a plant extract for attenuating NF-κB signaling, and γ-butyrobetaine or derivative thereof for inducing vasodilation. Administration of the composition of present invention provides a method for improving the skeletal muscle protein metabolism of an individual.
- In the following description, for the purposes of explanations, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one of ordinary skill in the art that the present invention may be practiced without these specific details.
- The present invention is directed towards improving skeletal muscle protein metabolism, both in terms of promoting increased muscle protein accrual via increased protein synthesis and in terms of reducing the breakdown of skeletal muscle protein. The present invention is particularly useful for individuals engaged in regular intense physical activity who wish to gain lean muscle mass and size or minimize muscle loss.
- In an embodiment of the present invention, a nutritional composition comprised of BCAAs is provided. The BCAAs employed may be selected from Leucine, Isoleucine and Valine or derivatives of each thereof.
- In an embodiment of the present invention, a nutritional composition comprised of BCAAs and at least one ingredient known to attenuate NF-κB signaling is provided. In a preferred embodiment the ingredient known to attenuate NF-κB signaling is an extract of Andrographis paniculata.
- In an embodiment of the present invention, a nutritional composition comprised of BCAAs, at least one ingredient known to attenuate NF-κB signaling and at least one ingredient known to increase vasodilation via increased levels of nitric oxide is provided. In a preferred embodiment the ingredient known to increase vasodilation via increased levels of nitric oxide is γ-butyrobetaine or derivatives thereof.
- In a preferred embodiment of the present invention, a nutritional composition comprised of Leucine, Isoleucine and Valine or derivatives of each thereof, an extract of Andrographis paniculata and γ-butyrobetaine or derivatives thereof is provided for improving skeletal muscle protein metabolism.
- The branched-chain amino acids (BCAAs) consist of Leucine, Isoleucine and Valine. BCAAs are considered essential since humans cannot synthesis them—they must be obtained from the diet—despite their importance. They are not only used in the synthesis of other amino acids but are important in the regulation of the anabolic process in skeletal muscle. BCAAs not only increase the rate of protein synthesis but also inhibit protein degradation (Matthews D E. Observations of branched-chain amino acid administration in humans. J Nutr. June 2005;135(6 Suppl):1580S-4S).
- In various embodiment of the present invention detailed in examples 1 and 2 below, the nutritional supplement comprises BCAAs or derivatives thereof. The amount of BCAAs or derivatives thereof in a serving of the nutritional supplement is from about 0.7 g to about 10.5 g.
- The preferred embodiment of the present invention comprises the BCAAs Leucine, Isoleucine and Valine or derivatives of each thereof in the following amounts. A serving of the nutritional supplement comprises Leucine or derivatives thereof from about 0.5 g to about 8.0 g. A serving of the nutritional supplement comprises Isoleucine or derivatives thereof from about 0.07 g to about 3.0 g. A serving of the nutritional supplement comprises Valine or derivatives thereof from about 0.1 g to about 3.5 g. Furthermore, in the preferred embodiment of the present invention, the ratio of Isoleucine to Leucine to Valine in the nutritional composition is about 1 to 2.3 to 1.2.
- Andrographis paniculata
- Andrographis paniculata is a medicinal herb used traditionally throughout Asia used to treat a number of conditions. One of the active ingredients of Andrographis paniculata extract is the diterpene, andrographolide. (Shen Y C, Chen C F, Chiou W F. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol. January 2002;135(2):399-406). Andrographolide is known to inhibit the activity of NF-κB by interfering with the binding of NF-κB to DNA (Hidalgo M A, Romero A, Figueroa J, Cortes P, Concha I I, Hancke J L, Burgos R A. Andrographolide interferes with binding to nuclear factor-κB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol. March 2005;144(5):680-6).
- In various embodiment of the present invention detailed in examples 1 and 2 below, the nutritional supplement comprises an extract of Andrographis paniculata. The amount of Andrographis paniculata extract in a serving of the nutritional supplement is from about 0.05 g to about 1 g. The preferred amount of Andrographis paniculata extract in a serving of the nutritional supplement is about 0.1 g.
- In additional embodiments, the present invention may also include additional components known to attenuate NF-κB-mediated signaling to promote the efficacy of the composition. For example, the nutritional supplement may further comprise Diferuloylmethane (Curcumin) (Singh S, Aggarwal B B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] J Biol Chem. Oct. 20, 1995;270(42):24995-5000. Erratum in: J Biol Chem Dec. 15, 1995;270(50):30235) or Ethyl pyruvate (Pyruvic Acid Ethyl Ester) (Das UN. Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. Med Sci Monit. May 2006;12(5):RA79-84). Ethyl pyruvate also has the benefit of providing an energy substrate beta-oxidation in the mit
- γ-butyrobetaine
- γ-butyrobetaine is an intermediate in carnitine biosynthesis in mammals. It is synthesized, from trimethyl lysine, in almost all cell types and then excreted into the blood to be reabsorbed by the kidney and liver. After reabsorption, γ-butyrobetaine is converted to carnitine by γ-butyrobetaine dioxygenase. This conversion to carnitine is extremely efficient, thus presence of γ-butyrobetaine in urine is very small (Vaz F M, Wanders R J A. Carnitine biosynthesis in mammals. Biochem J. 2002;361:417-429).
- The administration of γ-butyrobetaine to rats (Sjakste N, Kleschyov J L, Baumane L, Dzintare M, Meirena D, Sjakste J, Sydow K, Munzel T, Kalvinsh I. Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate. Eur J Pharmacol. Jul. 8, 2004; 495(1):67-73 (Abstract)), provides vasodilating activities. These vasodilating activities were attributed to increases in nitric oxide concentrations in blood.
- In various embodiment of the present invention detailed in examples 1 and 2 below, the nutritional supplement comprises γ-butyrobetaine or derivatives thereof. The amount of γ-butyrobetaine or derivatives thereof in a serving of the nutritional supplement is from about 0.01 g to about 1 g. The preferred amount of γ-butyrobetaine or derivatives thereof in a serving of the nutritional supplement is about 0.2 g.
- Not wishing to be bound by theory, it is believed that the components of the present invention will act synergistically and simultaneously to promote improved protein metabolism in skeletal muscles. The BCAAs or derivatives thereof will act to increase skeletal muscle protein synthesis while decreasing skeletal muscle protein breakdown; the Andrographis paniculata extract and other like-directed components will act to attenuate inflammatory signals mediated by NF-κB resulting from intense exercise; the of γ-butyrobetaine or derivatives thereof will act to vasodilate blood vessels via increase nitric oxide to facilitate the delivery of nutrients to active or recovering skeletal muscles.
- According to various embodiments of the present invention, the nutritional supplement may be consumed in any form. For instance, the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel. The preferred dosage form of the present invention is a caplet.
- Furthermore, the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above. Additionally, the nutritional supplement set forth in the example embodiment herein may contain any appropriate number and type of excipients, as is well known in the art.
- The inclusion of specific excipients, as well as specific dosage formats may be utilized to achieve specific controlled-release of active ingredients. Such formats include but are not limited to quick-release, timed-release, slow-release and delayed-release.
- The present nutritional composition or those similarly envisioned by one of skill in the art, may be utilized in methods to improve skeletal muscle protein synthesis. As such, the present invention may be utilized as a sole means of improving skeletal muscle protein synthesis or in combination with other like-directed compounds.
- Although the following examples illustrate the practice of the present invention in two of its embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one of skill in the art from consideration of the specifications and examples.
- A nutritional supplement in the form of caplets to be consumed twice daily. On workout days, one serving is to be taken 45 minutes before exercise and the second serving to be taken 30 minutes after exercise. On non-workout days, one serving is to be taken in the morning and the second serving to be taken in the afternoon. One serving of the nutritional supplement contains the following:
-
- about 1.75 g L-Leucine, about 0.001 g L-Leucine Ethyl Ester HCL, about 0.001 g N-Acetyl L-Leucine, about 0.93 g L-Valine, about 0.001 g L-Valine Ethyl Ester, about 0.001 g N-Acetyl L-Valine, about 0.77 g L-Isoleucine, about 0.001 g L-Isoleucine Ethyl Ester, about 0.001 g N-Acetyl L-Isoleucine, about 0.25 g Diferuloylmethane, about 0.10 g Andrographis paniculata extract (15% Andrographolide), and about 0.05 g Pyruvic Acid Ethyl Ester (ethyl pyruvate).
- A nutritional supplement in the form of caplets to be consumed twice daily. On workout days, one serving is to be taken 45 minutes before exercise and the second serving to be taken 30 minutes after exercise. On non-workout days, one serving is to be taken in the morning and the second serving to be taken in the afternoon. One serving of the nutritional supplement contains the following:
-
- about 3.55 g L-Leucine, about 0.001 g L-Leucine Ethyl Ester HCL, about 0.001 g N-Acetyl L-Leucine, about 1.85 g L-Valine, about 0.001 g L-Valine Ethyl Ester, about 0.001 g N-Acetyl L-Valine, about 1.54 g L-Isoleucine, about 0.001 g L-Isoleucine Ethyl Ester, about 0.001 g N-Acetyl L-Isoleucine, about 0.25 g Diferuloylmethane, about 0.10 g Andrographis paniculata extract, and about 0.05 g Pyruvic Acid Ethyl Ester (ethyl pyruvate).
- In the foregoing specification, the invention has been described with a specific embodiment thereof, however, it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention.
Claims (12)
1. A nutritional composition comprising at least
one or more branched-chain amino acids or derivatives thereof,
a plant extract, and
γ-butyrobetaine or derivative thereof
wherein said branched-chain amino acid acts to activate skeletal muscle protein synthesis and inhibit skeletal muscle protein degradation, said plant extract acts to attenuate NF-κB activity, and said γ-butyrobetaine or derivative thereof acts to increase vasodilation via increased levels of nitric oxide in a mammal.
2. The composition of claim 1 wherein the branched-chain amino acid is selected from, but not limited to, Leucine or derivatives thereof, Valine or derivatives thereof, and Isoleucine or derivatives thereof.
3. The composition of claim 1 wherein said plant extract is an extract of Andrographis paniculata.
4. The composition of claim 1 , further comprising an effective amount of ethyl pyruvate; wherein said ethyl pyruvate acts to increase substrate availability for mitochondrial beta-oxidation.
5. The composition of claim 1 , further comprising an effective amount of diferuloylmethane; wherein said diferuloylmethane acts to attenuate NF-κB activity.
6. A nutritional composition comprising an effective amount of at least one branched-chain amino acid, and effective amount of an extract of Andrographis paniculata, and an effective amount of γ-butyrobetaine or derivative thereof.
7. The composition of claim 6 wherein the branched-chain amino acid is selected from, but not limited to, Leucine or derivatives thereof, Valine or derivatives thereof, and Isoleucine or derivatives thereof.
8. The composition of claim 7 wherein said branched-chain amino acid acts to activate skeletal muscle protein synthesis or inhibit skeletal muscle protein degradation.
9. The composition of claim 6 wherein the extract of Andrographis paniculata acts to attenuate NF-κB activity.
10. The composition of claim 6 wherein the γ-butyrobetaine or derivative thereof acts to increase vasodilation via increased levels of nitric oxide.
11. The composition of claim 6 , further comprising an effective amount of ethyl pyruvate; wherein said ethyl pyruvate acts to increase substrate availability for mitochondrial beta-oxidation.
12. The composition of claim 6 , further comprising an effective amount of diferuloylmethane; wherein said diferuloylmethane acts to NF-κB activity.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/745,859 US20080279966A1 (en) | 2007-05-08 | 2007-05-08 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
US12/928,481 US7993685B2 (en) | 2007-05-08 | 2010-12-13 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/745,859 US20080279966A1 (en) | 2007-05-08 | 2007-05-08 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/928,481 Division US7993685B2 (en) | 2007-05-08 | 2010-12-13 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080279966A1 true US20080279966A1 (en) | 2008-11-13 |
Family
ID=39969769
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/745,859 Abandoned US20080279966A1 (en) | 2007-05-08 | 2007-05-08 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
US12/928,481 Expired - Fee Related US7993685B2 (en) | 2007-05-08 | 2010-12-13 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/928,481 Expired - Fee Related US7993685B2 (en) | 2007-05-08 | 2010-12-13 | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
Country Status (1)
Country | Link |
---|---|
US (2) | US20080279966A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2018186425A1 (en) * | 2017-04-06 | 2020-02-20 | 株式会社明治 | Fermented milk for increasing blood amino acid concentration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759061B2 (en) * | 2001-08-31 | 2004-07-06 | Renew Life, Inc. | Liver function improvement formulation |
US20060127492A1 (en) * | 2002-12-02 | 2006-06-15 | Meiji Dairies Corporation | Sustained improver of muscular fatigue |
-
2007
- 2007-05-08 US US11/745,859 patent/US20080279966A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/928,481 patent/US7993685B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759061B2 (en) * | 2001-08-31 | 2004-07-06 | Renew Life, Inc. | Liver function improvement formulation |
US20060127492A1 (en) * | 2002-12-02 | 2006-06-15 | Meiji Dairies Corporation | Sustained improver of muscular fatigue |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2018186425A1 (en) * | 2017-04-06 | 2020-02-20 | 株式会社明治 | Fermented milk for increasing blood amino acid concentration |
JP7168554B2 (en) | 2017-04-06 | 2022-11-09 | 株式会社明治 | Fermented milk for increasing blood amino acid concentration |
Also Published As
Publication number | Publication date |
---|---|
US7993685B2 (en) | 2011-08-09 |
US20110092587A1 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817329A (en) | Nutritional supplement for increased muscle size and strength for body builders | |
US8491943B2 (en) | Method and composition for improved anabolism | |
US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
US20120148685A1 (en) | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders | |
US20060286183A1 (en) | Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being | |
Goncharov et al. | Nutraceuticals in sports activities and fatigue | |
EP2941261B1 (en) | Synergistic curcuma and cissus compositions for enhancing physical performance and energy levels | |
Arazi et al. | Possible effects of beetroot supplementation on physical performance through metabolic, neuroendocrine, and antioxidant mechanisms: a narrative review of the literature | |
US20080138449A1 (en) | Composition and method for supporting thermogenesis and lipid oxidation | |
WO2003101469A1 (en) | An oral composition with insulin-like activities and methods of use | |
Han et al. | (‐)‐Hydroxycitric acid nourishes protein synthesis via altering metabolic directions of amino acids in male rats | |
WO2008134844A1 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
US7993685B2 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
Roysommuti et al. | The effects of taurine exposure on the brain and neurological disorders | |
Cholewa et al. | An overview of betaine supplementation, sports performance, and body composition | |
US20080279967A1 (en) | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid | |
US20200129580A1 (en) | Supplements and Methods for Glucose Control and Liver Support | |
McClung et al. | Effect of creatine supplementation on cardiac muscle of exercise-stressed rats | |
US20080279968A1 (en) | Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids | |
US20130280354A1 (en) | Composition and Method for Using Sage | |
Qazi et al. | Nutraceuticals in sports medicine | |
Pușcaș et al. | Meldonium Supplementation in Professional Athletes: Career Destroyer or Lifesaver? | |
US20230102471A1 (en) | Composition And Method for Modulating Hydrogen Ion Physiology Related to Weight Loss and Metabolism | |
WO2023026043A1 (en) | Nutritional compositions | |
Cahuê et al. | Enhancing satiety and aerobic performance with beer microparticles-based non-alcoholic drinks: exploring dose and duration effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MULTI FORMULATIONS LTD., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CLEMENT, KEN;CHAUDHURI, SHAN;MOLINO, MICHELE;AND OTHERS;REEL/FRAME:019531/0866 Effective date: 20070627 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |